Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDC Prevnar Guidance Will Urge Deferral Of Booster Dose During Shortage

Executive Summary

The Centers for Disease Control & Prevention will strengthen its recommendation that the booster dose of the pneumococcal conjugate vaccine (Wyeth's Prevnar) be delayed until supplies return to normal

You may also be interested in...



Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared

Improved supply for Wyeth/Amgen's Enbrel is allowing for the first significant increase in the number of patients on the TNF inhibitor in more than a year

Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared

Improved supply for Wyeth/Amgen's Enbrel is allowing for the first significant increase in the number of patients on the TNF inhibitor in more than a year

Wyeth Prevnar Capacity Expansion Planned For 2003; Shortage Until Then

Wyeth plans to add a second Prevnar production line during 2003 to help alleviate supply problems with the pneumococcal conjugate vaccine

Related Content

UsernamePublicRestriction

Register

PS038995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel